Severed Feet In Canada, The Mystery Of "Titanic's" Skeletons, John Wayne Gacy's Last Meal, And A Bunch Of Other Creepy Stuff
Do you love all things weird, dark, and creepy? Subscribe to the That Got Dark newsletter to get a weekly post just like this delivered directly to your inbox. It's a scary good time you won't want to miss.
Hello, friends! I'm Crystal, and I loooove going down a deep and dark rabbit hole, particularly late at night. And I wonder why I have trouble falling asleep…ha!
But, much like going to a scary movie, I don't like doing it alone. So, every week, I'll gather the darkest, weirdest, and creepiest things I find on the internet (and beyond) to share just with you, my spooky-loving friends. So, tuck yourself in tight and get out that flashlight…it's about to get dark.
Something that kept me up all night recently was the question: Where are the bones of the people who drowned when the Titanic sank? (Yes, these are the kinds of things I think about.)
We always see STUFF in photos and videos of the wreck — parts of the ship, fancy dishes, personal belongings like watches and shoes — but we never see human remains, specifically bones. I decided to do a little deep-diving (no pun intended) and found a very simple but absolutely nightmarish answer.
In an old NPR interview, deep-sea explorer Robert Ballard explained that the ship's wreck rests below the calcium carbonate compensation depth. What this means is that far down in the ocean, calcium carbonate (which is a primary component of bones) dissolves faster than it can accumulate. So, basically, after sinking to the bottom of the ocean floor, the victims' flesh was eaten by sea creatures, and then their bones DISSOLVED. Have fun thinking about that tonight.
Related: If You Get 12/15 On This Honors Vocab Quiz, Your IQ Has To Be At Least 150
Occasionally, I like to ask the BuzzFeed Community to tell me about the most mysterious, cult-like, bad-vibes towns in the United States they've ever been to. And you'd be shocked at how many responses I get each time (or maybe not). This week's spotlight: Vidor, Texas
'It's just east of Beaumont and still a sundown town. Local infrastructure vendors, i.e. Telco, power, etc., know to send only white workers to that town for safety. I've been through once, and it just feels off, but I was also traveling with a Black friend."
—Ok-disaster2022
Interesting fact: The 2017 film Three Billboards Outside Ebbing, Missouri was inspired by the murder of Kathy Page in Vidor, Texas, and the billboards her father, James Fulton, put up after demanding justice.
Wikipedia is like the Wild West. It's vast, lawless, and sometimes you can find some extremely weird things out there, like: the Salish Sea human foot discoveries
Since August of 2007, there have been at least 20 DETACHED human feet discovered off the coasts of British Columbia in Canada and Washington state in the US. There are a ton of theories as to why JUST feet have been found — ranging from boating accidents, plane crashes, suicide, foul play, and even the 2004 Indian Ocean tsunami — but no one really knows the truth and they probably never will.
Related: This Prom Dress Generator Will Help You Design Your Actual Dream Dress, And I'm Sort Of Obsessed With It
Anton Yelchin — Died: June 19, 2016, Cause of Death: Crushed by his Jeep Grand Cherokee
How he died: The promising young actor who starred in films like Odd Thomas and the popular Star Trek reboots was killed when his 2015 Cherokee rolled backward down the driveway of his Los Angeles home and then pinned him between the mailbox and security fence. His official cause of death was listed as 'blunt traumatic asphyxia.' Yelchin's parents eventually filed a lawsuit against Fiat Chrysler (the makers of the Jeep Grand Cherokee), as his vehicle was among 1.1 million others recalled. They reached a confidential settlement in 2018.
Strange Darling (2024)
What it's about: Nothing is what it seems when a twisted one-night stand spirals into a serial killer's vicious murder spree.
Why you should watch it: This acclaimed indie horror has a 96% rating on Rotten Tomatoes and Master of Horror himself, Stephen King, called it 'a clever masterpiece.'
Where you can watch it: Streaming for free on Paramount+ or for rent for $2.99 on Fandango at Home.
John Wayne Gacy
Known as the 'Killer Clown' — a moniker given because of his public appearances as a clown before the discovery of his crimes — John Wayne Gacy was a serial killer active in the Chicago area in the 1970s, who had at least 33 victims. He would rape and torture his victims — young men and boys — before killing them either by asphyxiation or strangulation. Gacy was executed by lethal injection in May 1994.
His last meal: A bucket of KFC chicken, 12 fried prawns, a pound of strawberries, French fries, and a Diet Coke.
Well, we survived another week, friend. In the next issue, I'll talk about a teenage TikToker who recklessly killed six people, a medieval torture device I can't believe was actually real, and Ted Bundy's last meal. Until then, stay safe, keep the lights on, and I'll see you for another horrifying trip down the rabbit hole…
Got a weird, creepy, or shocking story you want to share? Tell me all about it at thatgotdark@buzzfeed.com and, who knows, maybe it'll be featured in a future post or issue of That Got Dark!
Want more? Subscribe to the That Got Dark newsletter to get a weekly post just like this delivered directly to your inbox. It's a scary good time you won't want to miss.
Also in BuzzFeed: 37 School Scandals That Are So Wild, They Should Be Optioned For A Documentary
Also in BuzzFeed: These Visual Riddles Are Perhaps The Easiest Thing In The World To Solve — Can You Figure Them Out?
Also in BuzzFeed: Only "Former Gifted Kids" Will Know What These 24 Words Mean

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
26 minutes ago
- Medscape
DASH4D Diet for BP Control in T2D: Less Salt, Better Results
In adults with type 2 diabetes (T2D) on multiple antihypertensive medications, a modified Dietary Approaches to Stop Hypertension for Diabetes (DASH4D) diet combined with reduced sodium intake led to a clinically relevant reduction in systolic blood pressure (BP), with the benefits primarily attributed to sodium reduction. METHODOLOGY: Although the original DASH diet — rich in fruits, vegetables, and low-fat dairy products and low in saturated fat and cholesterol — is recommended with sodium reduction for managing hypertension in patients with T2D, evidence of its effectiveness in this population remains limited. Researchers conducted a single-site study in Maryland to assess the efficacy of the DASH4D diet, featuring lower carbohydrates, higher unsaturated fats, and lower potassium than the original DASH diet, together with reduced dietary sodium for BP management in T2D. They included 102 adults with T2D (mean age, 66 years; 66% women) between June 2021 and December 2023; the patients had a mean baseline BP of 135/75 mm Hg; 66% of them used at least two antihypertensive medicines, and 55% used two or more glucose-lowering medicines. Participants were randomly assigned to be provided with four diets in sequence, each for 5 weeks: The DASH4D diet with lower sodium, DASH4D diet with higher sodium, typical US diet with lower sodium, and typical US diet with higher sodium; in a 2000-kcal menu, the lower and higher sodium levels were set at 1500 mg/d and 3700 mg/d, respectively. The primary outcome was end-of-period systolic BP, measured on 5 separate days during the last 2 weeks of each feeding period. TAKEAWAY: Compared with patients on the typical US diet with higher sodium, those who received the DASH4D diet with lower sodium showed an average systolic BP reduction of 4.6 mm Hg (95% CI, -7.2 to -2.0) and an average diastolic BP reduction of 2.3 mm Hg (95% CI, -3.7 to -0.9) after 5 weeks. Among patients on the DASH4D diet, systolic BP was reduced by 4.8 mm Hg (95% CI, -7.4 to -2.2) in those with lower vs higher dietary sodium. Most reductions in BP occurred during the first 3 weeks of each diet period. Patients completely adhered to the recommended diet for 96% of the study days. The frequency of adverse events was low. IN PRACTICE: '[The findings] provide evidence of the efficacy of BP lowering through dietary change in people with T2D, including those treated with multiple antihypertensive and glucose-lowering medications,' the authors of the study wrote. 'High adherence to the DASH4D lower sodium diet suggests that the diet is acceptable.' SOURCE: This study was led by Scott J. Pilla, MD, MHS, Johns Hopkins University School of Medicine in Baltimore. It was published online on June 9, 2025, in JAMA Internal Medicine . LIMITATIONS: This study was not powered sufficiently to detect individual effects of the DASH4D diet and sodium reduction. As a single-center study, the study population lacked diversity. Participant feeding was disrupted at multiple points owing to the COVID-19 pandemic. DISCLOSURES: This study received funding from the Sheikh Khalifa Stroke Institute at Johns Hopkins University School of Medicine, grants from National Institute of Diabetes and Digestive and Kidney Diseases, National Heart, Lung, and Blood Institute grant, and the National Center for Advancing Translational Science Awards Program. Several authors reported receiving grants from sources including the funding agency and National Institutes of Health. Some authors reported serving on the scientific advisory board or receiving personal fees outside the submitted work.

Associated Press
26 minutes ago
- Associated Press
UP Aerospace Successfully Launches Maiden Flight of the Spyder Hypersonic Rocket
WHITE SANDS MISSILE RANGE, N.M., June 16, 2025 /PRNewswire/ -- UP Aerospace has achieved a significant milestone with the successful launch of its high-performance Spyder rocket. The maiden flight took place at 7:00 AM MST at Launch Complex 36, marking a new era in hypersonic mission capabilities. The mission reached the threshold of hypersonic speeds similar to the UP Aerospace SpaceLoft rocket missions that have been operational for 20 years. The mission was funded by the Stockpile Responsiveness Program (SRP) at Los Alamos National Laboratory (LANL) and was executed with the support of the Navy White Sands Detachment. The LANL payload test vehicle was successfully deployed in flight. Spyder was specifically designed to support hypersonic missions reaching speeds of Mach 10. The launch vehicle is the result of an eight-year collaboration between UP Aerospace, Cesaroni Aerospace, NASA's Flight Opportunities Program, Marshall Space Flight Center, and Los Alamos National Laboratory. Since 2005, UP Aerospace and Cesaroni Aerospace have worked closely to develop cutting-edge solid rocket motors technologies including the Spyder booster and upper stage motors. Future developments of Spyder include the maximum performance booster motor and multi upper stage Spyder variants capable of achieving altitude's approaching 300 km to support a wide variety of hypersonic mission objectives. For over 16 years UP Aerospace has been providing launch services supporting a variety of customers including NASA, the European Space Agency (ESA), and LANL, and began developing Spyder technologies under the NASA 'Tipping Point' contract awarded in 2017. The Spyder rocket was developed to provide enhanced mass lifting and speed performance capabilities to support thermal protection system development, re-entry capsule stability and control evaluations, and high speed suborbital flight testing capabilities at a greatly reduced time and cost. Jerry Larson, President and CEO of UP Aerospace, commented on the achievement: 'The successful launch of Spyder-1 sets the stage for the next mission, which will integrate guidance and control systems into the Spyder-2 vehicle. We are excited for its upcoming launch, scheduled for early 2026.' View original content to download multimedia: SOURCE UP Aerospace, Inc.

Associated Press
26 minutes ago
- Associated Press
AbTherx and GPCR Therapeutics Announce a Strategic Collaboration to Discover Novel Antibody-based Therapeutics for GPCR Targets
Partnership combines AbTherx's proprietary Atlas™ Long CDR3 Technology with GPCR Therapeutics' deep expertise in GPCR biology to discover and develop antibodies for novel targets MOUNTAIN VIEW, CA / ACCESS Newswire / June 16, 2025 / AbTherx, a biotechnology company with innovative technologies that enable therapeutic antibody discovery against challenging targets, today announced a research collaboration with GPCR Therapeutics, a clinical-stage biopharmaceutical company, to discover and develop therapeutic antibodies targeting G protein-coupled receptors (GPCRs) for one target, with the potential to expand to additional targets. AbTherx's antibody discovery platform is built on two decades of experience and utilizes the immune system's evolutionary intelligence to identify diverse and developable human antibodies. This collaboration leverages AbTherx's innovative, patent-pending Atlas Long CDR3 Mouse to create antibodies with long CDR3 regions, providing the unique opportunity to access buried epitopes within GPCRs, ion channels, and other difficult targets. These fully human antibodies minimize developability and immunogenicity risk by leveraging a rare, naturally occurring phenomenon in humans. GPCR Therapeutics is developing drugs targeting GPCRs to treat cancer, fibrosis, and obesity. Its stem cell mobilization program is now undergoing a phase 2 clinical trial in the United States of America. The company has also established capabilities for antigen development, antibody screening, and profiling for the discovery of antibodies targeting GPCRs, which are historically known to be challenging targets for antibody discovery. 'We are excited to strategically partner with GPCR Therapeutics to co-create a potentially life-saving therapeutic, leveraging the full power of the AbTherx team, combining a potentially best-in-class antibody discovery platform with a highly successful team of drug hunters,' said Justin Mika, CEO of AbTherx. 'This collaboration is a first for our proprietary Atlas Long CDR3 Mouse. We are keen to explore the full potential of this technology to discover and develop transformative, new antibody therapies for challenging targets.' 'We are thrilled to collaborate with one of the world's most experienced antibody discovery teams,' said Dong Seung Seen, CEO of GPCR Therapeutics. 'Our partnership with AbTherx marks a significant milestone for GPCR Therapeutics, strategically enhancing our ability to generate therapeutic antibodies against our priority targets. By combining our respective strengths, we aim to explore the largely uncharted territory of GPCR-targeting antibodies, ultimately striving to bring multiple first-in-class therapies to patients. The potential to expand our focus to additional targets in oncology, fibrosis, and obesity, further underscores the strategic value of this collaboration.' AbTherx has a range of partnering strategies from technology licensing to strategic collaborations. The Long CDR3 technology has the potential to deliver high-impact therapeutics for some of the most challenging targets. It is available for strategic research collaborations and co-development partnerships aimed at advancing innovative therapeutics. This AbTherx and GPCR Therapeutics partnership is expected to yield a pre-clinical asset governed by a 50/50 ownership structure, drawing on the complementary strengths and resources of both parties to develop a novel modality targeting GPCRs, the largest and most diverse family of drug targets. About AbTherx AbTherx is advancing medicine with revolutionary technologies that accelerate and enable therapeutic antibody discovery. Through an exclusive license from Gilead Sciences, AbTherx has released Atlas™ Mice, a suite of novel transgenic technologies designed for unmatched performance and Freedom to Operate. For over 20 years, a core group of AbTherx's scientists have worked together to push the boundaries of antibody discovery technologies, resulting in more than 1,000 successful discovery campaigns and the development of 13 marketed therapeutics. AbTherx's industry-leading team creates transformative solutions to overcome the most demanding challenges in delivering innovative medicines. Committed to making its technologies accessible to all, AbTherx offers flexible partnering models that meet the needs of drug developers of all sizes. For more information, please visit About GPCR Therapeutics GPCR Therapeutics, Inc. is a clinical-stage biopharmaceutical company taking an innovative approach to developing therapeutics based on its proprietary GPCR science. The company is currently conducting a Phase 2 clinical trial in the U.S. to evaluate the efficacy of GPC-100 in combination with propranolol in patients with multiple myeloma, in collaboration with Exicure. In addition to its lead program, GPCR Therapeutics is advancing multiple partnerships with pharmaceutical and biotech companies to develop therapies targeting cancer, fibrosis, obesity, and rare diseases. The company is headquartered in Seoul, South Korea. For more information, please visit AbTherx Media Contact Stacey Borders [email protected] SOURCE: AbTherx, Inc press release